Adopting what may be a unique therapeutic focus as a means whereby to bring change to a number of fibrotic diseases and Alzheimer's, Buto Corporation is tackling how to block pathophysiologic transitions that occur in these conditions. The firm's developed molecules have demonstrated efficacy in animal and human fibrosis, and in animal models of Alzheimer's disease. Buto's target - the SHC protein - has uniquely (in the world) developed small molecules that target the Shc protein a gatekeeper protein that modulates cell differentiation and pathophysiological transitions. To date, no other company has targeted this molecule.
